title: Long-term safety and efficacy are observed after implantation of Zotarolimus-Eluting stent in real-world clinical practice.
abstract: OBJECTIVE
  Zotarolimus-eluting stents (ZESs) have been shown to be safe and effective in randomised trials. We sought to report the clinical outcomes after implantation of ZES in real-world clinical practice.
  
  
  RESULTS
  ZES have been approved for clinical use in Singapore since April 2005. Until December 31, 2007, a total of 219 patients had undergone implantation of ZES. After excluding 11 foreign patients with whom contact was lost, 208 patients (246 lesions, 305 stents) formed the study cohort. A high-proportion of diabetic patients (n=90, 43.3%) was included. Recommended dual antiplatelet therapy was at least 3 months (n=147) for patients treated before or 12 months (n=61) after January 2007. As of January 2008, the median follow-up duration was 19 months (range: 1 to 33 months). There were 10 (4.8%) deaths, including 7 (3.4%) cardiac deaths. Myocardial infarction occurred in 11 (5.3%) patients. The numbers of patients requiring target vessel revascularisation and target lesion revascularisation were 10 (4.8%) and 5 (2.4%) respectively. Using the ARC definition, there were two cases of definite stent thrombosis on days 7 and 17, and one case of probable stent thrombosis on day 15.
  
  
  CONCLUSIONS
  In this real-world clinical experience, ZES was associated with a low incidence of adverse cardiac events at a medium follow-up of one and half years.
authors.affiliation: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. mdclchr@nus.edu.sg
authors.forename: Chi-Hang
authors.initials: CH
authors.lastname: Lee
authors.forename: Adrian F
authors.initials: AF
authors.lastname: Low
authors.forename: Eric C T
authors.initials: EC
authors.lastname: Hong
authors.forename: Bee-Choo
authors.initials: BC
authors.lastname: Tai
authors.forename: Ing-Haan
authors.initials: IH
authors.lastname: Lim
authors.forename: Swee-Guan
authors.initials: SG
authors.lastname: Teo
authors.forename: Yean-Teng
authors.initials: YT
authors.lastname: Lim
authors.forename: Huay-Cheem
authors.initials: HC
authors.lastname: Tan
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality*; D003324:Coronary Artery Disease / Q000401:mortality* / Q000628:therapy*; D023903:Coronary Restenosis / Q000401:mortality; D003328:Coronary Thrombosis / Q000188:drug therapy / Q000401:mortality; D016757:Death, Sudden, Cardiac; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007297:Inpatients / Q000706:statistics & numerical data; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; C489443:zotarolimus; D020123:Sirolimus